Physician profile
Ann L Edmunds
NPI 1417995192
$86,598.53
in general payments reported to CMS, 2019-2025
23 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $86.26 · 2021: $15K · 2022: $8,390 · 2023: $601 · 2024: $1,241 · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Consulting Fee: $5,460 · Food and Beverage: $3,931 · Travel and Lodging: $3,571 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,073.60 |
| Consulting Fee | $5,460.00 |
| Food and Beverage | $3,931.21 |
| Travel and Lodging | $3,571.03 |
| Education | $186.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $43,296.29 | 2022-2025 | |
| Alk-Abello, INC | $20,055.17 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $14,169.38 | 2021-2025 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $5,754.81 | 2025 | Dupixent |
| Smith+Nephew, INC. | $2,433.17 | 2019-2025 | Tula |
| Acclarent, INC | $182.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $135.34 | 2025 | Tezspire |
| Glaxosmithkline, LLC. | $107.46 | 2022-2025 | Nucala |
| Inspire Medical Systems, INC. | $73.91 | 2024 | Inspire |
| Cochlear Americas | $42.73 | 2021 | |
| Abbvie INC. | $40.06 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $40.05 | 2019 | |
| Stryker Corporation | $36.24 | 2019-2021 | |
| Amgen INC. | $34.02 | 2025 | Tezspire |
| Biocryst US Sales Co., LLC | $30.60 | 2025 | Orladeyo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $27.62 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.77 | 2023 | |
| Zimvie INC. | $23.83 | 2024 | |
| Olympus America INC. | $22.47 | 2023 | |
| Hikma Pharmaceuticals USA | $18.81 | 2024 | Ryaltris |
| Optinose US, INC. | $18.66 | 2023 | |
| Merck Sharp & Dohme LLC | $15.18 | 2023 | |
| Allergan, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Edmunds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.